| CORRECTION: Capricor Therapeutics | 06/25 10:30 | globenewswire.com |
| Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy | 06/25 08:30 | globenewswire.com |
| Capricor: Rolling BLA Submission Of CAP-1002 To Get DMD Treatment Program Going | 06/17 13:44 | seekingalpha.com |
| Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway | 06/11 09:25 | globenewswire.com |
| Capricor (CAPR) Advances in DMD Therapy With Positive Study Data | 06/10 10:40 | zacks.com |
| Capricor Therapeutics, Inc. (CAPR) Q1 2024 Earnings Call Transcript | 05/14 03:03 | seekingalpha.com |
| Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates | 05/13 18:15 | zacks.com |
| Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | 05/13 16:05 | globenewswire.com |
| Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting | 05/09 09:15 | globenewswire.com |